Compare Abeona Therapeutics Inc (ABEO) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Manulife Financial Corporation — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Manulife Financial Corporation trades at $43.84 (market cap $73.19B). The key difference: Manulife Financial Corporation is far larger — about 172.5× Abeona Therapeutics Inc's market cap, and Manulife Financial Corporation pays a 3.08% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MFC | |
|---|---|---|
Market Cap | $424.33M | $73.19B |
Sector | Health | Financials |
52-Week High | $7.45 | $44.77 |
52-Week Low | $4.17 | $29.90 |
Enterprise Value | $279.23M | $68.35B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Manulife Financial (MFC) trades at $44.32, down 0.58% with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 results with double-digit growth in Asia and insurance sales, beating EPS expectations. Revenue reached $53.01B in 2025 with net income of $5.78B, though profit margins have moderated from 2022 peaks. Analysts maintain a Moderate Buy consensus with 57% buy ratings.
MFC presents a positive investment case with solid earnings growth, expanding Asian operations, and consistent dividend payments. However, premium valuation metrics and moderating profit margins warrant caution. The stock faces risks from wealth management outflows and competitive pressures in core markets, requiring careful monitoring of Q3 earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
